Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

Human Gene Therapy

Volumn 11, Issue 1, 2000, Pages 191-204

  Aukerman, S L ^a,b  

^a Selective Genetics Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR 2; GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE THERAPY; HERPES SIMPLEX VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

EID: 77953082198     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050016265     Document Type: Article

References (65)

1. Baird, A., and Klagsbrun, M. (1991). The fibroblast growth factor family. Cancer Cells 3, 239-243.
2. Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
3. Birnbaum, D., Delapeyriere, O., Adnane, J., Dionne, C., Crumley, G., Jaye, M., Schlessinger, J., Xerri, L., Escot, C., Gaudray, P., and Theillet, C. (1991). Role of FGFs and FGF receptors in human carcinogenesis. Ann. N.Y. Acad. Sci. 638, 409-411.
4. Blanckaert, V.D., Hebbar, M., Louchez, M.M., Vilain, M.-O., Schelling, M.E., and Peyrat, J.-P. (1998). Basic fibroblast growth receptors and their prognostic value in human breast cancer. Clin. Cancer Res. 4, 2939-2947.
5. Chandler, L., Sosnowski, B., Greenlees, L., Aukerman, S.L., Baird, A., and Pierce, G. (1999). Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int. J. Cancer 81, 451-458.
6. Chen, H.-H., Mack, L.M., Kelly, R., Ontell, M., Kochanek, S., and Clemens, P.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
7. Cone, R.W., and Fairfax, M.R. (1993). Protocol for ultraviolet irradiation of surfaces to reduce PCR contamination. PCR Methods Appl. 3, S15-S17.
8. Dai, Y., Schwarz, E.M., Gu, D., Zhang, W.-W., Sarvetnick, N., and Verma, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
9. Douglas, J.T., Rogers, B.E., Rosenfeld, M.E., Michael, S.I., Feng, M., and Curiel, D.T. (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotechnol. 14, 1574-1578.
10. Doukas, J., Hoganson, D.K., Ong, M., Ying, W., Lacey, D.L., Baird, A., Pierce, G.F., and Sosnowski, B.A. (1999). Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J. 13, 1459-1466.
11. Fang, B., Eisensmith, R.C., Li, X.H.C., Finegold, M.J., Shedlovsky, A., Dove, W., and Woo, S.L.C. (1994). Gene therapy for phenylketonuria: Phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1, 247-254.
12. Fox, J.C., Ait-Khaled, M., Webster, A., and Emery, V.C. (1991). Eliminating PCR contamination: Is UV irradiation the answer? J. Virol. Methods 33, 375-382.
13. Franz, W.-M., Rothmann, T., Frey, N., and Katus, H. (1997). Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc. Res. 35, 560-566.
14. Gao, G.-P., Yang, Y., and Wilson, J.M. (1996). Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70, 8934-8943.
15. Gilgenkrantz, H., Duboc, D., Juillard, V., Couton, D., Pavirani, A., Guillet, J.G., Briand, P., and Kahn, A. (1995). Transient expression of genes transferred in vivo into the heart using first-generation adenoviral vectors: Role of the immune response. Hum. Gene Ther. 6, 1265-1274.
16. Goldman, C.K., Rogers, B.E., Douglas, J.T., Sosnowski, B.A., Ying, W., Siegal, G.P., Baird, A., Campain, J.A., and Curiel, D.T. (1997). Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57, 1447-1451.
17. Graham, F.L., and Prevec, L. (1991). Manipulation of adenovirus vectors. In Methods in Molecular Biology. E.J. Murray, ed. (Humana Press, Clifton, NJ) pp. 109-128.
18. Gu, D.-L., Gonzalez, A.M., Printz, M.A., Doukas, J., Ying, W., D'Andrea, M., Hoganson, D.K., Curiel, D.T., Douglas, J.T., Sosnowski, B.A., Baird, A., Aukerman, S.L., and Pierce, G.F. (1999). Fibroblast growth factor-2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 59, 2608-2614.
19. Hu, S.-X., Ji, W., Zhou, Y., Logothetis, C., and Xu, H.-J. (1997). Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor α gene expression. Cancer Res. 57, 3339-3343.
20. Huard, J., Lochmüller, H., Acsadi, G., Jani, A., Massie, B., and Karpati, G. (1995). The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2, 107-115.
21. Ilan, Y., Droguett, G., Chowdhury, N.R., Li, Y., Sengupta, K., Thummala, N.R., Davidson, A., Chowdhury, J.R., and Horwitz, M.S. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. U.S.A. 94, 2587-2592.
22. Juillard, V., Villefroy, P., Godfrin, D., Pavirani, A., Venet, A., and Guillet, J.-G. (1995). Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 25, 3467-3473.
23. Kamantigue, E., Edwards, W., III, Chada, S., Brumm, D., Austin, M., Irwin, M., Mento, S., Kowal, K., and Sajjadi, N. (1996). Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther. 3, 128-136.
24. Kaplan, J.M., Armentano, D., Sparer, T.E., Wynn, S.G., Peterson, P.A., Wadsworth, S.C., Couture, K.K., Pennington, S.E., St. George, J.A., Gooding, L.R., and Smith, A.E. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8, 45-56.
25. Kay, M.A., Landen, C.N., Rothenberg, S.R., Taylor, L.A., Leland, F., Wiehle, S., Fang, B., Bellinger, D., Finegold, M., Thompson, A.R., Read, M., Brinkhous, K.M., and Woo, S.L.C. (1994). In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. U.S.A. 91, 2353-2357.
26. Kim, S., Lin, H., Barr, E., Chu, L., Leiden, J.M., and Parmacek, M.S. (1997). Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J. Clin. Invest. 100, 1006-1014.
27. Kobrin, M.S., Yamanaka, Y., Freiss, H., Lopez, M.E., and Korc, M. (1993). Abberant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 53, 4741-4744.
28. Kornmann, M., Beger, H.G., and Korc, M. (1998). Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17, 169-175.
29. Krasnykh, V.N., Mikheeva, G.V., Douglas, J.T., and Curiel, D.T. (1996). Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70, 6839-6846.
30. Kuzmin, A.I., Finegold, M.J., and Eisensmith, R.C. (1997). Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther. 4, 309-316.
31. Larocca, D., Witte, A., Gonzalez, A.M., and Houston, L.L. (1998). Establishment of epitope-defined monoclonal antibodies with specificity for fibroblast growth factor receptor types 1 and 2. Hybridoma 17, 21-31.
32. Li, Y., Pong, R.-C., Bergelson, J.M., Hall, M.C., Sagalowsky, A.I., Tseng, C.-P., Wang, Z., and Hsieh, J.-T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
33. Lindner, V., and Reidy, M.A. (1993). Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ. Res. 73, 589-595.
34. McClane, S.J., Chirmule, N., Burke, C.V., and Raper, S.E. (1997). Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for readministration. Hum. Gene Ther. 8, 2207-2216.
35. Michael, S.I., Hong, J.S., Curiel, D.T., and Engler, J.A. (1995). Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 2, 660-668.
36. Morrison, R., Yamaguchi, F., Bruner, J.M., Tang, M., McKeehan, W., and Berger, M.S. (1994). Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res. 54, 2794-2799.
37. Müllbacher, A., Bellet, A.J.D., and Hla, R.T. (1989). The murine cellular immune response to adenovirus type 5. Immunol. Cell. Biol. 67, 31-39.
38. Niederhauser, C., Höfelein, C., Wegmüller, B. Lüthy, J., and Candrian, U. (1994). Reliability of PCR decontamination systems. PCR Methods Appl. 4, 117-123.
39. Ramakrishnan, R., Fink, D.J., Jiang, G., Desai, P., Glorioso, J.C., and Levine, M. (1994). Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J. Virol. 68, 1864-1873.
40. Rancourt, C., Rogers, B.E., Sosnowski, B.A., Wang, M., Piché, A., Pierce, G.F., Alvarez, R.O., Siegal, G.P., Douglas, J.T., and Curiel, D.T. (1998). Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin. Cancer Res. 4, 2455-2461.
41. Rogers, B., Douglas, J., Sosnowski, B., Ying, W., Pierce, G., Buschbaum, D., Dellamanna, D., Baird, A., and Curiel, D. (1998). Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting 3, 25-31.
42. Sarkar, G., and Sommer, S.S. (1991). Parameters affecting susceptibility of PCR contamination to UV inactivation. BioTechniques 10, 590-594.
43. Schulick, A.H., Vassalli, G., Dunn, P.F., Dong, G., Rade, J.J., Zamarron, C., and Dichek, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. J. Clin. Invest. 99, 209-219.
44. Simon, R.H., Engelhardt, J.F., Yang, Y., Zepeda, M., Weber-Pendleton, S., Grossman, M., and Wilson, J.M. (1993). Adenovirus-mediated transfer of the CFTR gene to the lung of non human primates: Toxicity study. Hum. Gene Ther. 4, 771-780.
45. Smith, T.A.G., Mehaffey, M.G., Kayda, D.B., Saunders, J.M., Yei, S., Trapnell, B.C., McClelland, A., and Kaleko, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397-402.
46. Stevenson, S.C., Rollence, M., White, B., Weaver, L., and McClelland, A. (1995). Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J. Virol. 69, 2850-2857.
47. Takanami, I., Tanaka, F., Hashizume, T., Kikuchi, K., Yamamoto, Y., Yamamoto, T., and Kodaira, S. (1996). The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers. Eur. J. Cancer 32A, 1504-1509.
48. Tomko, R.P., Xu, R., and Philipson, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
49. Ueba, T., Takahashi, J.A., Fukumoto, M., Ohta, M., Ito, N., Oda, Y., Kikuchi, H., and Hatanaka, M. (1994). Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 34, 221-226.
50. Van Ginkel, F.W., Liu, C., Simecka, J.W., Dong, J.-Y., Greenway, T., Frizzell, R.A., Kiyono, H., McGhee, J.R., and Pascual, D.W. (1995). Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum. Gene Ther. 6, 895-903.
51. Volm, M., Koomägi, R., Mattern, J., and Stammler, G. (1997). Prognostic value of basic fibroblast growth factor and its receptor (FGFR1) in patients with non-small cell lung carcinomas. Eur. J. Cancer 33, 691-693.
52. Vrancken-Peeters, M.-J., Lieber, A., Perkins, J., and Kay, M. (1996a). Method for multiple portal vein infusions in mice: Quantitation of adenovirus-mediated hepatic gene transfer. BioTechniques 20, 278-285.
53. Vrancken-Peeters, M.-J., Patijn, G.A., Lieber, A., Meuse, L., and Kay, M.A. (1996b). Adenovirus-mediated hepatic gene transfer in Mice: Comparison of intravascular and biliary administration. Hum. Gene Ther. 7, 1683-1699.
54. Watkins, S.J., Mesyanzhinov, V.V., Kurochkina, L.P., and Hawkins, R.E. (1997). The "adenobody" approach to viral targeting: Specific and enhanced adenoviral gene delivery. Gene Ther. 4, 1004-1012.
55. Wickham, T.J., Segal, D.M., Roelvink, P.W., Carrion, M.E., Lizonova, A., Lee, G.M., and Kovesdi, I. (1996a). Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70, 6831-6838.
56. Wickham, T.J., Roelvink, P.W., Brough, D.E., and Kovesdi, I. (1996b). Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnol. 14, 1570-1573.
57. Wickham, T.J., Lee, G.M., Titus, J.A., Sconocchia, G., Bakács, T., Kovesdi, I., and Segal, D.M. (1997a). Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol. 71, 7663-7669.
58. Wickham, T.J., Tzeng, E., Shears, L.L., II, Roelvink, P.W., Li, Y., Lee, G.M., Brough, D.E., Lizonova, A., and Kovesdi, I. (1997b). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.
59. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R.G. (1997a). Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8, 37-44.
60. Worgall, S., Leopold, P.L., Wolff, G., Ferris, B., Van Roijen, N., and Crystal, R.G. (1997b). Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum. Gene Ther. 8, 1675-1684.
61. Yamaguchi, F., Saya, H., Bruner, J.M., and Morrison, R.S. (1994). Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc. Natl. Acad. Sci. U.S.A. 91, 484-488.
62. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gönczöl, E., and Wilson, J.M. (1994a). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
63. Yang, Y., Ertl, H.C.J., and Wilson, J.M. (1994b). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1, 433-442.
64. Yang, Y., Li, Q., Ertl, H.C.J., and Wilson, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
65. Yee, D., McGuire, S.E., Brünner, N., Kozelsky, T.W., Allred, D.C., Chen, S.-H., and Woo, S.L.C. (1996). Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum. Gene Ther. 7, 1251-1257.